Samsung Biologics explores AI-powered manufacturing solutions

AI News


Samsung Biologics CEO John Lim views Samsung Electronics' exhibit at CES 2026 in Las Vegas on Wednesday. Provided by Samsung Biologics

Samsung Biologics CEO John Lim views Samsung Electronics' exhibit at CES 2026 in Las Vegas on Wednesday. Provided by Samsung Biologics

LAS VEGAS — Samsung Biologics CEO John Lim attended CES 2026 last week to explore artificial intelligence (AI)-driven digital transformation strategies in manufacturing.

“By attending CES, you can experience global trends in advanced technology and gain insight into manufacturing innovation in the AI ​​era,” said Mr Lim.

He also participated in various sessions during CES, including Caterpillar's keynote and discussions on AI adoption in manufacturing and automation-based smart factory technologies.

Traditionally a consumer electronics and IT show, CES has evolved into a broader platform encompassing AI, robotics, healthcare, and other industries undergoing digital transformation. This year, we focused on AI, digital health, and advanced mobility, with a particular focus on “physical AI,” or technologies that allow AI systems to interact directly with the real world.

Nvidia CEO Jensen Huang said: [and] The most important thing is physical AI,” he said, highlighting the important role of innovation in manufacturing, with global companies such as Siemens and Caterpillar highlighting plans to adopt digital twins and smart factory technologies.

Digital manufacturing innovation is also accelerating in the pharmaceutical and biotech sectors.

Samsung Biologics has evolved its manufacturing execution system and quality execution system to provide customized services to customers around the world. Recently commissioned, Plant 5 employs AI and digital twin technology to automate processes, optimize quality control, and improve productivity. Electronic manufacturing records and autonomous mobile robots further ensure data integrity and minimize process errors.

After CES, Mr. Lim will attend the JPMorgan Healthcare Conference in San Francisco from Monday to Thursday (local time), where he will present Samsung Biologics' digital transformation strategy and long-term vision.

Building on last year's efforts, Lim will also meet with executives and investors to expand the company's global network and strengthen the company's credibility.



Source link